No products in the cart.
Pre-made Tamrintamab benchmark antibody ( Whole mAb ADC, anti-DPEP3 therapeutic antibody, Anti-MBD3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-547
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tamrintamab biosimilar, Whole mAb ADC, Anti-DPEP3 Antibody: Anti-MBD3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tamrintamab pamozirine, also known as SC-003, is an ADC composed of a proprietary antibody against DPEP3 (dipeptidase 3) also known as MBD3, a glycosylphosphatidylinositol anchored membrane protein from the DPEP family of dipeptidase proteins.
| Products Name (INN Index) | Pre-Made Tamrintamab biosimilar, Whole mAb ADC, Anti-DPEP3 Antibody: Anti-MBD3 therapeutic antibody |
|---|---|
| INN Name | Tamrintamab |
| Target | DPEP3 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | 6vgr:HL:CD |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Stemcentrx |
| Conditions Approved | NA |
| Conditions Active | Ovarian cancer,Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | DPEP3 |
| Package |
Previous slide
Next slide
